HC Wainwright Reiterates Buy Rating on Mineralys Therapeutics
HC Wainwright reiterated its Buy rating and $56 price target on Mineralys Therapeutics. The target implies 139.6% upside from the Oct. 9 close of $23.37.
Story updates
11:45:19 AM UTC
SquawkNews
Mineralys Therapeutics Price Target Maintained With a $56.00/Share by HC Wainwright & Co.